WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO aims at promoting scientific excellence in fundamental life sciences research and translating scientific achievements in medical, pharmaceutical and veterinary biotechnology applications.
Immunotherapy generated undreamt-of results in the treatment of aggressive and advanced metastatic cancer. But it occurred only one-fourth to one-third of patients are responding positively, leaving a large majority that didn’t respond to immunotherapy. Explaining why and increasing immunotherapy’s efficiency were the research objectives of Benoît Van den Eynde, WELBIO investigator at UCL’s de Duve Institute and director of the Brussels Branch of the Ludwig Cancer Research Institute. The results of this study were published in Nature Communications.
T cells, the cells of our immune system that can kill the tumor, barely infiltrate the tumor. What halts T cell infiltration is far from being understood. Researchers of the de Duve Institute (Pierre van der Bruggen’s team, WELBIO Investigator at the Catholic Université of Louvain) have discovered a novel mechanism by which tumor cells reduce T cell infiltration. The results of this study have been published in Nature Communications.
In 2016, WELBIO supported twenty-two research programs through the Fund for Strategic Fundamental Research (F.R.S. (Fonds de la Recherche Scientifique) [Fund for Scientific Research]-FNRS) as well as three WELBIO Bridge Fund projects. These researches are, among others, carried out in the fields of neurobiology, genetic, immunology and cancer biology. Moreover, the new Board of Directors adopted its 2020 strategic plan, based on 4 main axes.